Cell Therapy Market Outlook:
Cell Therapy Market size was over USD 14.22 billion in 2025 and is anticipated to cross USD 76.34 billion by 2035, witnessing more than 18.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of cell therapy is assessed at USD 16.56 billion.
It is believed that the rising incidence of cancer across the globe is driving this market expansion. The Food and Drug Administration (FDA) has approved CAR T-cell therapies, bringing them into the mainstream for the management of multiple myeloma, leukemia, and lymphomas.
As per the World Health Organization (WHO), it is anticipated that there will be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of cell therapy is assessed at USD 16.56 billion.
The global cell therapy market size surpassed USD 14.22 billion in 2025 and is projected to witness a CAGR of around 18.3%, crossing USD 76.34 billion revenue by 2035.
North America cell therapy market will dominate around 59% share by 2035, driven by increased medical R&D and healthcare expenditure.
Key players in the market include Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, JCR Pharmaceuticals Co., Ltd., JW Therapeutics, Atara Biotherapeutics.
